Amylyx Pharmaceuticals (NASDAQ: AMLX)
Amylyx Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Amylyx Pharmaceuticals Company Info
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
News & Analysis
3 Under-the-Radar Biotech Stocks to Buy in 2023
These three lesser-known biotech companies are profitable and growing revenue.
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
These two high-tech bio companies may be too cheap to ignore right now.
Why Shares of Amylyx Pharmaceuticals Were Up Monday
The company got a bump from an analyst's upgrade.
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?
Which of these red-hot biotech stocks is the better buy right now?
2 Supercharged Growth Stocks to Buy Right Now
These two biopharma stocks might be poised for a major breakout.
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
The biopharma's new ALS drug is exceeding projections on the sales front.
3 IPO Stocks That You Want to Own
This down market is giving us some really intriguing stocks at cheap prices.
This Stock Has Delivered a Gain of 100% Over the Past 3 Months. Can You Still Buy?
Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.